Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment

Ähnliche Einträge

• Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment
  von: Tinhofer, Ingeborg, et al.
  Veröffentlicht: (2011)
• EGFRvIII vaccine in glioblastoma: nACT-IVe or not ReACTive enough?
  von: Platten, Michael
  Veröffentlicht: (2017)
• Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie
  von: Knödler, Michael, et al.
  Veröffentlicht: (2013)
• Clustered localization of EGFRvIII in glioblastoma cells as detected by high precision localization microscopy
  von: Boyd, Philip S., et al.
  Veröffentlicht: (2016)
• Contribution of human papilloma virus to the incidence of squamous cell carcinoma of the head and neck in a European population with high smoking prevalence
  von: Tinhofer, Ingeborg, et al.
  Veröffentlicht: (2015)